The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n = 2 12.

A dry composition for use in therapy or diagnosis, obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, such as TRIS, lactate, lysine and histidinc wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffer h...

An aqueous composition comprising a therapeutic protein further characterized in that (i) the pH of the composition is adjusted to be between about 5.9 and 6.3, preferably about 6.1; (ii) the composition comprises at least one displaced buffer having a pKa within 1 to 3 pH units of the pH of the composition such as ...

An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands or strong...

An aqueous vaccine composition comprises a protein adsorbed on a solid and one or more stabilising agents wherein the one or more stabilising agents have ionisable groups capable of exchanging protons with the protein and with the ionised products of water dissociation, and wherein the ionisable groups include first...

There is provided inter aliaan aqueous liquid pharmaceutical formulation comprising (i) an insulin compound (ii) ionic zinc (iii) a zinc binding species at a concentration of mM or more selected from species having a logK with respect to zinc ion binding in 5 the range 4.5-12.3 at 25 °C and (iv) a non-ionic surfacta...

There is provided inter aliaan aqueous liquid pharmaceutical formulationcomprising (i) an insulincompound at a concentration of 500-1000 U/ml (ii) ionic zinc (iii) a zinc binding species at a concentration of 1 mM or more selected from species having a logK with respect to zinc ion binding in the range 4.5-12.3 at 2...

According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue ionic zinc a chelating agent and polysorbate 80.

There is provided inter alia an aqueous solution composition comprising a GLP-1 receptor agonist as an active ingredient and multivalent anions having a charge of at least minus 2 as stabilising agent wherein the total concentration of multivalent anions in the composition having a charge of at least minus 2 is at l...

The present invention relates inter alia to an aqueous liquid pharmaceutical formulation comprising: (i) an insulin compound; (ii) ionic zinc; (iii) a zinc binding species at a concentration of 1 mM or more selected from species having a logK with respect to zinc ion binding in the range 4.5-10 at 25 °C; (iv) a zinc...

The present invention relates inter alia to an aqueous liquid pharmaceutical formulation comprising (i) an insulin compound (ii) ionic zinc (iii) a nicotinic compound (iv) a non-ionic surfactant; and (v) a salt selected from the salts formed between Group 1 metals and a mono or divalent anion. It also provides relat...

There is provided inter alia an injection pen system comprising an injector mechanism and a reservoir comprising an aqueous liquid pharmaceutical composition for delivery by means of said injector mechanism to a mammal wherein the composition comprises (i) an insulin compound, (ii) ionic zinc and (iii) an alkyl glyc...

There is provided inter aliaa medical infusion pump system comprising a pump and a reservoir comprising an aqueous liquid pharmaceutical composition for delivery by means of said pump to a mammal wherein the composition comprises (i) an insulin compound at a concentration of 400 U/mLor more, (ii) ionic zinc and (iii...

There is provided, inter alia, an aqueous solution composition of pH in the range 4.0-7.5 comprising: a peptide therapeutic agent; optionally one or more buffers being substances having at least one ionisable group with a pKa in the range 3.0 to 8.5 and which pKa is within 2 pH units of the pH of the composition; an...

There is provided inter alia an aqueous solution composition comprising insulin glargine as an active ingredient and an amino acid selected from aspartic acid and glutamic acid as a stabilising agent wherein the amino acid is present at a concentration of 1-50 mM.

There is provided inter alia an aqueous solution composition comprising insulin glargine as an active ingredient and triethylenetetramine (TETA) as a stabilising agent.

There is provided inter alia medical infusion pump system comprising a pump and a reservoir comprising an aqueous liquid pharmaceutical composition for delivery by means of said pump to a mammal wherein the composition comprises (i) an insulin compound, (ii) ionic zinc and (iii) an alkyl glycoside as a non-ionic sur...

The invention provides inter alia an aqueous solution composition of pH in the range 6.0 to 8.0 comprising: -daptomycin or an analogue thereof, or a salt thereof; -a divalent metal cation; and -one or more salts which are not divalent metal cation salts or amino acid salts or buffer salts at a total concentration of...

There is provided inter alia an aqueous solution composition of pH in the range 5.0 to 8.0 comprising: - daptomycin or an analogue thereof, or a salt thereof; - a divalent metal cation; and - optionally one or more buffers being substances having at least one ionisable group with a pKa in the range 3.0 to 9.0 and wh...

The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concen...